Core Insights - STRATA Skin Sciences, Inc. has published a study confirming the superiority of its 308nm Excimer laser combined with a JAK inhibitor over monotherapy, indicating significant market growth potential and expanded treatment indications [1][2][4] Study Findings - The study involved 251 patients and demonstrated five key findings regarding the combination therapy: 1. Mechanistic synergy between JAK inhibitors and Excimer laser promoting effective treatment [6] 2. Superior efficacy with a 14.20% higher repigmentation rate compared to monotherapy [6] 3. Unprecedented response rates with a 100% significant efficacy rate after 52 weeks of treatment [6] 4. Durable stability with a 96.5% pigmentation stability rate and an 8.8% relapse rate at one-year follow-up [6] 5. Excellent safety profile with no serious or persistent adverse events reported [6] Clinical Validation - The study adds to over 400 existing studies validating the efficacy of the 308nm Excimer laser as a cornerstone therapy for various dermatologic conditions, including vitiligo and psoriasis [3][4] Market Position - STRATA's Excimer laser technology has been in use for around 20 years, and dermatologists continue to rely on its performance for durable repigmentation in challenging skin conditions [2][4] Future Directions - The company is pursuing expanded reimbursement for its treatment modalities and aims to provide broader access by early 2026 [3]

Core Insights - STRATA Skin Sciences, Inc. has highlighted a recent study demonstrating the efficacy of its 308nm Excimer laser combined with a JAK inhibitor for treating localized non-segmental vitiligo, showing superior results compared to monotherapy [1][2][4] Study Findings - The study involved 251 patients and revealed five key findings: 1. Mechanistic synergy between JAK inhibitors and Excimer laser therapy [7] 2. A 14.20% higher repigmentation rate with the combination therapy [7] 3. A 100% significant efficacy rate after 52 weeks of treatment [7] 4. At one-year follow-up, the combination group showed 96.5% pigmentation stability and an 8.8% relapse rate [7] 5. The treatment exhibited an excellent safety profile with no serious adverse events [7] Clinical Validation - The study adds to over 400 existing studies validating the 308nm Excimer laser as a cornerstone therapy for various inflammatory and autoimmune skin diseases [3][4] - The combination therapy is positioned as a personalized medicine approach, allowing for tailored treatment based on laser exposure duration and dosage [3] Company Strategy - The company is pursuing expanded reimbursement for its treatments, leveraging the strong clinical evidence from the recent study [3][4] - STRATA continues to work with regulators to enhance access to its treatment modalities by early 2026 [3]